

CURRICULUM VITAE

I. PERSONAL INFORMATION

First name: Pascual Izquierdo

Family name: Cristina

Address: C/ Principado de Asturias, 49 D.P.: 28231

Movil phone number: +34 651555156

Social Security, Passport, ID number: 01116994E

E-mail: crisizquierdo3@yahoo.es

II. CURRENT POSITION:

- Hematology and Hemotherapy Specialist responsible for the Haemostasis and Thrombosis Unit (laboratory and clinic) of the Hematology and Hemotherapy Service of the Gregorio Marañón University Hospital from January 1995 until now.
- Tutor of Residents since 2012 until may 2021.

III. EDUCATION:

- Licensed in Medicine and Surgery by Autonoma University Medicine of Madrid. July 1987.
- Specialist in Hematology and Hemotherapy. 1992
- Medicine PhD by Complutense University of Madrid in 2015. Qualification of Apto “Cum Laude” for Unanimity.
- Master degree in clinical management from the Pompeu Fabra University, Barcelona, 2019.

TEACHING EXPERIENCE

- Instructor for residents in hematology (2012-now).
- Organizer of annual courses on thromboembolic disease and ITP.

- Collaborating professor of Medical Pathology, at the Complutense University of Madrid since 1995.
- Collaborating professor of Anatomy, at the Carlos III University of Madrid since 2010.
- Head of studies of the school of Clinical laboratory technicians “Gregorio Marañón, since 1999-since 2017.

PROFESSIONAL MEMBERSHIPS

- Board membership of Spanish Society of Hematology since 2014-now
- Board membership of CAT (Spanish Society of Hematology) since 2014-now
- Board membership of working group of Thrombotic Thrombocytopenic Purpura (TTP) Spanish group since 2017-now
- Board membership of GEA since 2020 (Spanish Apheresis group)
- Board membership of GEPTI (Immune Thrombocytopenic Purpura Spanish group since 2017-now

IV. RESEARCH PROJECTS

- Associate Researcher of the Project: ANALYSIS OF PROTROMBOTIC FACTORS IN PROTECTION SURGERY HIP AND KNEE. Principal Investigator: Ignacio Garuti, Financing Entity: Mutual Participating Entities: Gregorio Marañón Hospital Duration: from 2005 - 2006
- Associate researcher in the project IMMUNE RECONSTITUTION EVALUATION AFTER THE HAPLOIDENTIC TRANSPLANTATION OF HEMOPOYETIC PROGENITORS WITHOUT DEPRESSION T. Mutual Project. 2012
- Associate researcher in the project, TREATMENT OF SEVERE ALLOGEN POST-TRANSPLANTING HEMORRAGICAL CYSTITIS WITH MESENQUIMAL CELLS. Principal Investigator: JORGE GAYOSO

Financing Entity: Ministry of Health. Aid for Independent Research.
Participating Entities: Gregorio Marañon Hospital DURATION SINCE: 2011
UNTIL: 2012

- Associate researcher in the project ASSESSMENT OF IMMUNE RECONSTITUTION AFTER THE HAPLOIDENTIC TRANSPLANTATION OF HEMOPOYETIC PROGENITORS WITHOUT DEPRESSION T. Principal Investigator:: JL DIEZ
FINANCING ENTITY: MUTUAL
PARTICIPATING ENTITIES: GREGORIO MARAÑON HOSPITAL
DURATION SINCE: 2012 UNTIL: 2014
- Associate Researcher in the Project QUANTIFICATION OF MESENQUIMAL MOTHER CELLS INFUSED IN THE TREATMENT OF DIAGNOSTICATED PATIENTS OF AVASCULAR NECROSIS OF THE HEAD OF FEMUR
Principal Investigator:: DAVID SERRANO
FINANCING ENTITY: MAFRE
PARTICIPATING ENTITIES: GREGORIO MARAÑON HOSPITAL
DURATION SINCE: 2012 UNTIL: 2015
- Associate researcher in the project Donor NK cells post-transplant infusion, in patients with acute leukemia of poor prognosis undergoing transplantation has not been manipulated Haploidentical. "Funded by the Carlos III Health Institute.
Principal Investigator: J.L Díez Martin
FINANCING ENTITY: MINISTRY OF HEALTH. AID FOR INDEPENDENT RESEARCH. -FIS Project PI15 / 00879. Call 2015.
PARTICIPATING ENTITIES: GREGORIO MARAÑON HOSPITAL
Duration from 2016 to 2018

RESEARCH SCHOLARSHIPS ORGANIZED BY OTHER AGENCIES

- Principal investigator of the “Open study of repeated doses with Eltrombopag Olamine (SB-497115-GR) in adults with Idiopathic Thrombocytopenic Purpura” (PTI), code TRA108057, sponsored by GlaxoSmithKline and started in May 2007.
- Principal investigator of the EXTEND Study, prolonged treatment with Eltrombopag Olamine, in adults with idiopathic thrombocytopenic purpura, sponsored by GSK and initiated in 2008.
- Associate researcher of the “Multicentre study of the safety and efficacy of Sym001 (AA4420220) in adults with Idiopathic Thrombocytopenic Purpura (PTI) Rh positive and not splenectomized”, code Sym001-03, sponsored by MDS Pharma and started in Oct-2007.
- Associate researcher of the open study in phase 3b “Treatment with Romiplostin in patients with chronic ITP, protocol number: 2004029, amendment version 4 of August 14, 2008, sponsored by Amgen.
- Principal investigator of the study: Treatment with Dalteparin / Fragmin in patients with VTE and cancer sponsored by INC Research.
- Principal investigator of the “Open study of repeated doses with Eltrombopag olamine (SB-497115-GR) in adults with Idiopathic thrombocytopenic Purpura” (PTI), code TRA108057, sponsored by GlaxoSmithKline and started in May 2007.
- Principal investigator of the EXTEND Study, prolonged treatment with Eltrombopag Olamine, in adults with idiopathic thrombocytopenic purpura, sponsored by GSK and initiated in 2008.
- Associate researcher of the "Multicentre study of the safety and efficacy of Sym001 (AA4420220) in adults with Idiopathic Thrombocytopenic Purple (PTI) Rh positive and not splenectomized", code Sym001-03, sponsored by MDS Pharma and started in Oct-2007.

- Associate researcher of the open study in phase 3b “Treatment with Romiplostin in patients with chronic ITP, protocol number: 2004029, amendment version 4 of August 14, 2008, sponsored by Amgen..
- Principal investigator of the study: Immunoglobulins in PTI-Financial institution: LB research, started in Oct 2012.
- 17. Principal investigator of the study Phase III clinical study, a series of cases on the reversal of anticoagulant treatment of dabigatran, by intravenous administration of 5.0 grams of idarucizumab (BI 655075) in patients treated with dabigatran who have uncontrolled hemorrhage or require surgical intervention or urgent intervention procedure. Financial institution Boheringer Ingelheim.
- Principal investigator of the project <Multicenter, retrospective, observational study according to clinical practice of patients treated with dabigatran administered for the prevention of cardioembolic episodes in patients with non-valvular atrial fibrillation. > CODE: HEM-01-13,Version 1.0 of November 29, 2013
- Associate researcher of the “Evaluation of purified poloxamer 188 in vaso-occlusive crisis of sickle cell disease: a phase 3 randomized, double blind placebo-controlled multicenter clinical trial of MST-188 injection in subjects with sickle cell disease experiencing vaso-occlusive crisis. MAST-188-01.
- Principal investigator A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (Protocol v1.0, 05June2015).
- Principal investigator of the WEUKBRE STUDY7133 project. "REVIEU - Multinational, retrospective and observational study on the use of the REVOLADE TM drug (eltrombopag) in selected countries of the European Union"

- National Coordinator and Principal Investigator of the Project: Multicenter, randomized, prospective, open study to evaluate the clinical safety and efficacy of normal human immunoglobulin for intravenous administration BT595 in patients with chronic primary thrombocytopenia (ITP). Biotest.
- Principal investigator of the study A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment, recently started. (Takeda)
- Principal investigator of the study A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER) (Novartis), currently recruiting.
- Principal investigator of the PREDIGA observational study "Report for the study of splenomegaly and splenectomized patients not affiliated in children and adults, currently recruiting. Sanofi.
- Principal investigator of the LNP023L12201 An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders (currently recruiting_ Novartis).
- Principal investigator of the LUNA study_ A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

VI. RELEVANT MERITS

PUBLICATIONS:

1. Abdominal presentation of varicella zoster infection after bone marrow transplantation” Perez-Oteyza, Pascual C, Garcia- Laraña J, Odriozola J, Rocamora A, Navarro JL. Bone Marrow Transplant 1992; 9(3):217.
2. Antiphospholipid antibodies en migrañie” Iniguez C. Pascual C, Pardo A, Martinez-Castrillo JC, , Alvarez-Cermeno JC. Headache 1991; 31(10): 666-668.
3. Antithrombotic Therapy in non neoplastic Chronic Portal Venous. Mi Kwon, A. R Huerta, Cristina Pascual, et al. Blood, 2006,108A 894
4. Anti Vit K treatment in patients with Fontan Surgery. M. Infante, Cristina Pascual, et al. Blood 2010, 116 A 4397
5. Natural Killer cell reconstitution after haploidentical unmanipulated bone marrow transplantation with reduced intensity conditioning. I Gonzalez Gascon, A perex Corral J Gayoso, J Anguita, C Pascual et al. Blood 2011 118 A4557
6. Antitrombotic Therpay in non-neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: recanalization and liver function evaluation. L. Bento, A R Huerta, C. Pascual et al. Blood 2011 118 A 3358
7. Immune reconstitution after autologos stem cell transplantation: Is there any diference between HIV+ and HIV -. M. Bastos, A. Roldan, J Anguita, C. Pascual, et al. Blood, 2012 120 A 4665.
8. Value of pretranplantation minimal residual disease in acute Myeloid Leukemia and Myeloabaltive Hematopietic cell transplantation. L. Bento, M Kwon, I buño, C Martines, P Basalobre, J Anguita, A P Corral, C. Pascual. Blood 2012 120 A 2510.
9. Haploidentical transplantation (HAPLO) with post-transplant High dose cyclofosfamida for graft vs host disease prevention in the treatment of high risk

- hematological neoplasm. J Gayoso, M Kown, D Serrano, P Basallobre, C Pascual et al. *Blood* 2012 120 A4545.
10. Haploidentical stem cell transplantation (Haplo-HSCT) with reduced intensity conditioning regimens and high dose cyclophosphamide post-transplant as Gvhd prophylaxis in patients with relapsed or refractory Hodgkin's in patients with relapses or refractory Hodgkin's Disease: multicentric Spanish Experience. J. Gayoso, Pascual Balsalobre, C. Castilla, MJ Pascual, M Kown, C. Pascual. Et al. *Blood* 2013 122(21)
 11. Mismatches in killer Immunoglobulin receptor (KIR) ligands and inhibitory KIR receptors between donor and recipients improve survival after non T cell depleted haploidentical transplantation. M. Bastos, J. Anguita, C. Martínez Laperche, P. Balsalobre, C. Muñiz, C. Pascual et al. *Blood* 2013 122 (21).
 12. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Martínez-Martínez I, Navarro-Fernández J, Østergaard A, Gutiérrez-Gallego R, Padilla J, Bohdan N, Miñano A, Pascual C, Martínez C, de la MorenaBarrio ME, Aguila S, Pedersen S, Kristensen SR, Vicente V, Corral J. *Blood*. 2012 Jul 26;120(4):900-4. Epub 2012 Apr 12.
 13. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. González-López TJ, Sánchez-González B, Pascual C, Arefi M, de Cabo E, Alonso A, Martín-Salces M, Jiménez-Bárceñas R, Calbacho M, Galan P, Barez A, González-Porras JR. *Platelets*. 2014 Feb 5. [Epub ahead of print] PMID:24499036
 14. A new case of successful outcome of pregnancy in a carrier of homozygous type II (L99F) antithrombin deficiency. Pascual C, Muñoz C, Huerta AR, Rus GP, Ortega V, Corral J, Díez-Martín JL. *Blood Coagul Fibrinolysis*. 2014 Jan;25(1):74-6. doi: 10.1097/MBC.0b013e3283646620.

15. Lymphocyte subpopulations analysis of extracorporeal photopheresis products in graft versus host disease treatment. *Biol Blood Marrow Transpl* 2014: , PH-AB154. C.Pascual, L.Bento, MJ Penalva¹, AM. Pérez Corral¹, M. Bastos¹, L. Solan¹, D. Serrano^{1,2}, J. Gayoso^{1,2}, P. Balsalobre^{1,2}, M. Kwon^{1,2}, J. Anguita^{1,2}, JL Díez Martín^{1,2}.
16. L. Bento¹, C. Pascual¹, AM. Pérez Corral¹, J. Anguita^{1,2}, , I. González Gascón y Marín¹, D. Serrano^{1,2}, J. Gayoso^{1,2}, P. Balsalobre^{1,2}, M. Kwon^{1,2}, JL Díez Martín^{1,2}. Lymphocyte Subpopulations Analysis Of Extracorporeal Photopheresis Products In Graft Versus Host Disease Treatment. *Biol Blood Marrow Transpl* 2012: 18 (2): S354 A 405.
17. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Saleh MN¹, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Chong B, Pidcock M, Pabinger-Fasching I, Olney H, Arnold D, Assouline S, Shen Z, Yang R, Sun A, Mayer J, Pohlreichova V, Hlusi A, Marcher C, Nousiainen T, Godeau B, Cheze S, Viallard J, Ganser A, Matzdorff A, Salama A, Schroeder D, Schroeder D, von Depka Prondzinski M, Hiller E, Rummel M, Anagnostopoulos A, Poziopoulos C, Wong R, Fabris F, Ciceri F, Angelini F, Vianelli N, Kim B, Novotný V, Biamond BJ, Schipperus MR, Wittebol S, Blacklock H, Simpson D, Ganly P, Doocey R, Shamsi T, Aziz Z, Murillo S, Ulloa V, Kloczko J, Dmoszynska A, Robak T, Kuliczowski K, Homenda W, Calbecka M, Antonio Stoia R, Vladareanu A, Kovaleva L, Rukavitsyn O, Domnikova N, Abdulkadyrov K, Palasthy S, Reimana JA, Lazur J, Escudero Soto A, Besalduch J, Páramo Fernández J, Gerosa S, Ribera Santasusana J, Perez Crespo S, Alonso A, **Pascual Izquierdo C**, Wadenvik H, Lerner R, Tsay W, Rojnuckarin P, Sirijerachai C, Meddeb B, M'Sadek F, Khelif A, Davies S, Nokes T, Grech

- H, Al-Ismail S, Scully M, Martlew V, Masliak Z, Kaplan P, Cosgriff T, Giudice R, Hon J, Kuriakose P, Liebman H, Flynn P, Smith D, Fogarty P, Quick D, de Oliveira M, Taylor M, Gernsheimer T, Pullarkat V, Rarick M, Scroggin C Jr, George J, Soong Ahn Y, Kuter D, Tarantino M, McCrae K, Phan L, Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, Bento L, Pascual C, Kwon M, Balsalobre P, Muñoz C, Buces E, Serrano D, Gayoso J, Buño I, Anguita J, Díez-Martín JL. Eur J Haematol. 2014 Apr 5. doi: 10.1111/ejh.12336.
19. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation. Bastos-Oreiro M, Anguita J, Martínez-Laperche C, Fernández L, Buces E, Navarro A, Pascual C, Pérez-Corral A, Balsalobre P, Muñoz C, Kwon M, Serrano D, Perez-Martinez A, Buño I, Gayoso J, Díez-Martín JL. Eur J Haematol. 2016 May;96(5):483-91. Epub 2015 Jul. Accepted for publication jun 2015.
20. Impact of the ENDORSE study results on thromboprophylaxis prescribing patterns in medical patients attending the emergency department. de Lorenzo-Pinto A¹, García-Sánchez R, Pascual Izquierdo C, Durán-García ME, Castuera-Gil AI, Andueza-Lillo JA, Sanjurjo-Sáez M. Int J Clin Pract. 2015 Jan;69(1):81-6. doi: 10.1111/ijcp.12461. Epub 2014 May 23.
21. Use of eltrombopag after romiplostim in primary immune thrombocytopenia . González-Porras JR¹, Mingot-Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC, Fernández-Fuertes F, Cortti MJ, Pascual C, Sánchez-González B, Bernat S, Fuertes-Palacio MA, Vázquez-Paganini JA, Olivera PE, Alvarez-Román MT, Jarque I, Cortés M, Martínez-Robles

- V, Díaz-Gálvez FJ, Calbacho M, Fernández-Miñano C, García-Frade J, González-López TJ. Br J Haematol. 2014 Dec 18. doi: 10.1111/bjh.13266. [Epub ahead of print].
22. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. José González-López T¹, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Corti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, García-Frade J, González-Porras JR. Am J Hematol. 2014 Nov 17. doi: 10.1002/ajh.23900. [Epub ahead of print]
23. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. **Gayoso J**, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115.
24. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. González-López TJ, Álvarez-Román MT, **Pascual C**, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Núñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Miñano C, de Cabo E, Fisac R, Aguilar C, Báez A, Peñarrubia MJ, García-Frade LJ, González-Porras JR. Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725.

25. Fatal anaphylaxis caused by gadolinium due to beta-tryptase-induced hemorrhagic diathesis. Prieto-García A, Pérez-David E, Devesa C, Tornero P, Schwartz LB, Pascual C, Castells MC. *J Allergy Clin Immunol Pract*. 2017 Sep - Oct;5(5):1433-1434. doi: 10.1016/j.jaip.2017.05.008. Epub 2017 Jun 19.
26. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Pérez-Rus G, Hernández-Rivas JA, Bernat S, Bastida JM, Martínez-Badas MP, Martínez-Robles V, Soto I, Olivera P, Bolaños E, Alonso R, Entrena L, Gómez-Nuñez M, Alonso A, Yera Cobo M, Caparrós I, Tenorio M, Arrieta-Cerdán E, Lopez-Ansoar E, García-Frade J, González-Porras JR. *Br J Haematol*. 2017 Sep;178(6):959-970. doi: 10.1111/bjh.14788.
27. Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre]. García Morin M, Cela E, Garrido C, Bardón Cancho E, Aguado Del Hoyo A, Pascual C, Pérez-Corral A, Beléndez C. *An Pediatr (Barc)*. 2017 Mar;86(3):142-150.
28. Level de concordance between two risk assessment models for predicting venous thromboembolism in medical patients admission. Ana de Lorenzo de Pinto, Raquel García Sanchez, Esther Durán, Ana Castuera, Cristina Pascual, et al , *Eur J Hosp Pharm* 2016, 23; 141-144.
29. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, Sánchez-González B, Martínez-Robles V, Alvarez-Román MT, Pérez-Rus G, Pascual C, Bernat S, Arrieta-Cerdán E, Aguilar C, Báez A, Peñarrubia MJ, Olivera P, Fernández-Rodríguez A, de Cabo E, García-Frade LJ, González-Porras JR. *Int J Hematol*. 2017 Oct;106 (4):508-516. doi: 10.1007/s12185-017-2275-4. Epub 2017 Jun 30. PMID:28667351

30. Transient hemolysis due to anti-D and anti-A1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. Bailén R, Kwon M, Pérez-Corral AM, Pascual C, Buño I, Balsalobre P, Serrano D, Gayoso J, Díez-Martín JL, Anguita J. *Transfusion*. 2017 Oct;57(10):2355-2358.
31. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. Bailén R, Pérez-Corral AM, Pascual C, Kwon M, Serrano D, Gayoso J, Balsalobre P, Muñoz C, Díez-Martín JL, Anguita J. *J Clin Apher*. 2019 Aug;34(4):373-380. doi: 10.1002/jca.21685. Epub 2019 Jan 29. PMID: 30694583.
32. Mononuclear cell collection for extracorporeal photopheresis by using the "off-line" system: A comparative study between COBE Spectra and Spectra Optia devices. Pascual C, González-Arias E, Pérez-Corral AM, Bailén R, Gayoso J, Besson N, Serrano D, Kwon M, Anguita J, Díez-Martín JL. *J Clin Apher*. 2019 Aug;34(4):359-366. doi: 10.1002/jca.21679. Epub 2018 Dec 14.
33. Oarbeascoa G, Lozano ML, Guerra LM, Amunarriz C, Saavedra CA, Garcia-Gala JM, Viejo A, Revilla N, Acosta Fleitas C, Arroyo JL, Martinez Revuelta E, Galego A, Hernandez-Maraver D, Kwon M, Diez-Martin JL, Pascual C; Grupo Español de Aféresis – Spanish Apheresis Group. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2020 Apr;26(4):651-658. doi: 10.1016/j.bbmt.2019.12.769. Epub 2020 Jan 7. PMID: 31917270.
34. Santos A, Macías N, Vega A, Abad S, Linares T, Aragoncillo I, Cruzado L, Pascual C, Goicoechea M, López-Gómez JM. Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration. *Clin Kidney J*. 2020 Jun 22;14(4):1120-1125. doi: 10.1093/ckj/sfaa057. PMID: 33841857; PMCID: PMC8023216.

35. González-López TJ, Sánchez-González B, Jarque I, Bernat S, Fernández-Fuertes F, Caparrós I, Soto I, Fernández-Rodríguez A, Bolaños E, Pérez-Rus G, Pascual C, Hernández-Rivas JA, López-Ansoar E, Gómez-Nuñez M, Martínez-Robles V, Olivera P, Yera Cobo M, Peñarrubia MJ, Fernández-Miñano C, de Cabo E, Martínez Badas MP, Perdomo G, García-Frade LJ. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. *Eur J Haematol*. 2020 Mar;104(3):259-270. doi: 10.1111/ejh.13370. Epub 2020 Feb 3. PMID: 31840311.

36. Cid J, Monsalvo S, Castillo C, Pascual C, Moreno-Jiménez G, López-Parra M, Andón C, Guerra L, Esquirol A, Sánchez-Ortega I, Ortega S, Zalba S, Martínez C, Rovira M, Marín P, Lozano M; Grupo Español de Trasplante Hematopoyético (GETH).. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH). *Transfus Apher Sci*. 2021 Apr;60(2):103052. doi: 10.1016/j.transci.2021.103052. Epub 2021 Jan 12. PMID: 33483284.

37. Pascual C, Nieto JM, Fidalgo T, Seguí IG, Díaz-Ricart M, Docampo MF, Del Rio J, Salinas R. Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay. *Int J Lab Hematol*. 2021 Jun;43(3):485-493. doi: 10.1111/ijlh.13414. Epub 2020 Dec 2. PMID: 33264480.

38. Regalado-Artamendi I, Pérez-Corral AM, García-Morín M, Cela E, Beléndez C, Bardón-Cancho EJ, Pérez-Rus G, Pérez-Sánchez I, Pascual C, Monsalvo S, Falero C, Díez-Martín JL, Anguita J. Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. *Blood Transfus*. 2021 Jul;19(4):292-299. doi: 10.2450/2020.0096-20. Epub 2020 Oct 14. PMID: 33085598; PMCID: PMC8297678.

39. Mingot-Castellano ME, Alcalde-Mellado P, Pascual-Izquierdo C, Perez Rus G, Calo Pérez A, Martinez MP, López-Jaime FJ, Abalo Perez L, Gonzalez-Porras JR, López Fernández F, Caparrós Miranda IS, González-López TJ, Moreno Beltrán ME, Rubio Escuin R, Jimenez Bárcenas R; on behalf GEPTI (Grupo Español de Trombocitopenia Inmune). Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain. *Br J Haematol*. 2021 Aug;194(3):537-541. doi: 10.1111/bjh.17506. Epub 2021 May 15. PMID: 33991422; PMCID: PMC8239889.
40. Rubia M, Cordero A, Pérez-Granda MJ, Cercenado E, Pascual C, Muñoz P, Guembe M. In Vitro Study To Evaluate the Bioactivity of Freezing a Heparin-Based Dalbavancin Lock Solution. *Antimicrob Agents Chemother*. 2020 Nov 17;64(12):e01495-20. doi: 10.1128/AAC.01495-20. PMID: 32988823; PMCID: PMC7674050.
41. de Miguel-Sanchez CJ, Arguello-Tomas M, Perez-Rus G, Vazquez-Allen P, Mijaylova-Antonova AG, Anaya F, Lopez-Esteban M, Diez-Martin JL, Gil-Núñez AC, Pascual-Izquierdo C. Plasma exchange as an effective salvage therapy in AZD1222 vaccine-induced thrombotic thrombocytopenia: a case report. *Blood Transfus*. 2021 Dec 2. doi: 10.2450/2021.0220-21. Epub ahead of print. PMID: 34967727.
42. Bastos-Oreiro M, Ortiz J, Pradillo V, Salas E, Marínez-Laperche C, Muñoz A, Buño I, Diéz-Martin JL, Soria JM, Pascual Izquierdo C. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. *Cancer Med*. 2021 Nov;10(21):7585-7592. doi: 10.1002/cam4.4280. Epub 2021 Oct 1. PMID: 34598309; PMCID: PMC8559493.
43. Martín-Rojas RM, Chasco-Ganuza M, Casanova-Prieto S, Delgado-Pinos VE, Pérez-Rus G, Duque-González P, Sancho M, Díez-Martín JL, Pascual-Izquierdo

- C. A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients. *Blood Coagul Fibrinolysis*. 2021 Oct 1;32(7):458-467. doi: 10.1097/MBC.0000000000001068. PMID: 34310402; PMCID: PMC8527912.
44. Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. *Expert Rev Hematol*. 2021 Aug;14(8):707-719. doi: 10.1080/17474086.2021.1956898. Epub 2021 Aug 4. PMID: 34275393.
45. Mingot Castellano ME, Pascual Izquierdo C, González A, Viejo Llorente A, Valcarcel Ferreiras D, Sebastián E, García Candel F, Sarmiento Palao H, Gómez Seguí I, de la Rubia J, Cid J, Martínez Nieto J, Hernández Mateo L, Goterris Vicedo R, Fidalgo T, Salinas R, Del Rio-Garma J; Grupo Español de Aféresis (GEA). Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. *Med Clin (Barc)*. 2021 Jul 12:S0025-7753(21)00332-8. English, Spanish. doi: 10.1016/j.medcli.2021.03.040. Epub ahead of print. PMID: 34266669.
46. Pascual-Izquierdo C, Del Rio-Garma J, de la Rubia J, Viejo A, Mingot E, Cid J, Solanich X, Fernández-Sojo J, Martín-Sánchez J, Hernández L, García-Gala JM, Alonso N, González V, Oliva A, Gómez-Seguí I, Goterris R, Guerra L, García-Candel F, Fernández-Docampo M, Antelo ML, Salgado-Barreira Á, Salinas R; Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT). Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura. *J Clin Apher*. 2021 Aug;36(4):563-573. doi: 10.1002/jca.21894. Epub 2021 Mar 29. PMID: 33780553.

47. Domingo-González A, Regalado-Artamendi I, Martín-Rojas RM, Pérez-Rus G, Pérez-Corral A, Díez-Martín JL, Pascual-Izquierdo C. Application of the French TMA Reference Center Score and the mortality in TTP Score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain. *J Clin Apher.* 2021 Jun;36(3):420-428. doi: 10.1002/jca.21880. Epub 2021 Feb 3. PMID: 33534947.
48. Martín-Rojas RM, Pérez-Rus G, Delgado-Pinos VE, Domingo-González A, Regalado-Artamendi I, Alba-Urdiales N, Demelo-Rodríguez P, Monsalvo S, Rodríguez-Macías G, Ballesteros M, Osorio-Prendes S, Díez-Martín JL, Pascual Izquierdo C. COVID-19 coagulopathy: An in-depth analysis of the coagulation system. *Eur J Haematol.* 2020 Dec;105(6):741-750. doi: 10.1111/ejh.13501. Epub 2020 Aug 19. PMID: 32749010; PMCID: PMC7436538.
49. Martínez-Solano J, Ortiz-Bautista C, Zatarain-Nicolás E, Sousa-Casasnovas I, Pedraz-Prieto Á, Barrio-Gutiérrez JM, Pascual-Izquierdo C, Fernández-Avilés F. Management of Intracranial Hemorrhage During Pulsatile Long-Term Biventricular Support: When Necessity Is the Mother of Invention. *ASAIO J.* 2021 Oct 1;67(10):e172-e175. doi: 10.1097/MAT.0000000000001353. PMID: 33528165.
50. Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. *N Engl J Med.* 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. PMID: 30625070.
51. Del Río-Garma J, Bobillo S, de la Rubia J, Pascual C, García-Candel F, García-Gala JM, Gonzalez R, Abril L, Vidan J, Gomez MJ, Peña F, Arbona C, Martín-Sanchez J, Moreno G, Romón I, Viejo A, Oliva A, Linares M, Salinas R, Pérez S, Garcia-Erce JA, Pereira A; “Registro Español de la Púrpura Trombocitopénica Trombótica (REPTT)”, and the “Grupo Español de Aféresis

- (GEA)”. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era. *Ann Hematol.* 2022 Jan;101(1):59-67. doi: 10.1007/s00277-021-04685-8. Epub 2021 Oct 12. PMID: 34642787.
52. Arribalzaga K, Martínez-Alfonzo I, Díaz-Aizpún C, Gutiérrez-Jomarrón I, Rodríguez M, Castro Quismondo N, Pérez-Fernández E, Velasco-Rodríguez D, Gómez E, Fernández B, Vilches A, Martín-Herrero S, Castilla L, Blanco MJ, Gutiérrez MDM, Rivas I, Pascual C, Rosado B, Sola E, Vidal-Laso R, Asenjo S, Mora Casado MA, Benito-Parra L, Carmona I, Marín K, Acedo N, García-León N, Marcheco A, Guillén C, Fernández C, Rodríguez R, Pardo L, Silva P, Montero L, Meijón M, Massó P, Llamas-Sillero P; Asociación Madrileña de Hematología y Hemoterapia (AMHH). Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region. *Thromb Res.* 2021 Jul;203:93-100. doi: 10.1016/j.thromres.2021.05.001. Epub 2021 May 8. PMID: 33989984; PMCID: PMC8106233.
53. Duque P, Chasco-Ganuzza M, Ortuzar A, Almaraz C, Terradillos E, Perez-Rus G, Pascual C. Acquired FXIII Deficiency is Associated with High Morbidity. *Thromb Haemost.* 2021 Apr 13. doi: 10.1055/a-1481-2733. Epub ahead of print. PMID: 33851388.
54. Santos A, Macías N, Vega A, Abad S, Linares T, Aragoncillo I, Cruzado L, Pascual C, Goicoechea M, López-Gómez JM. Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis? *Ther Apher Dial.* 2022 Feb;26(1):147-153. doi: 10.1111/1744-9987.13652. Epub 2021 Apr 29. PMID: 33890717.
55. Díaz-Navarro M, Hafian R, Manzano I, Pérez-Granda MJ, Cercenado E, Pascual C, Rodríguez C, Muñoz P, Guembe M. A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing. *Infect Dis Ther.* 2022 Jan 16. doi: 10.1007/s40121-021-00579-4. Epub ahead of print. PMID: 35034289.

56. Cristina Pascual Izquierdo, Pascual Piñera Salmerón, Francisco Tembourny et al. Immune thrombotic thrombocytopenic purpura: suspect and basic management in the emergency departments. review and consensus from a group of experts . *Emergencias 2022, in press.*
57. Rubio-Azpeitia E, Pérez-Corral AM, Dorado-Herrero N, Monsalvo S, Pérez-Balsera G, Fernández-Santos ME, Kwon M, Oarbeascoa G, Bastos-Oreiro M, Falero C, Pascual Izquierdo C, Muñoz-Martínez C, Pérez-Martínez A, Díez-Martin JL, Anguita J. Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. *Transfusion.* 2022 Jan 13. doi: 10.1111/trf.16790. Epub ahead of print. PMID: 35023148.
58. C. Pascual-Izquierdo, a. Domingo-Gonzalez. Prediction of Severity and Mortality in Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Utility of Clinicalbiological Scores. *Journal of Clinical Haematology (2021) Volume 2, Issue 2. ISSN: 2766-4686*

BOOKS:

- Coordinator-Author of the Hematology chapters of the book “ DIAGNOSTICO Y TRATAMIENTO MEDICO” *DTM, editorial Marban 2009.1ª edición.*
- Coordinator-Author of the Hematology chapters of the book DIAGNOSTICO Y TRATAMIENTO MEDICO” *DTM, editorial Marban 2013.2ª edición.*
- Autora y editora del libro “Diagnóstico, Tratamiento médico”. Editorial Marban Edición 2009. ISBN 978-84-7101-637-9
- Coordinator-Author of the Hematology chapters of the book.-“Diagnóstico, Tratamiento médico”. Editorial Marban Edición 2011. 3 capítulos: Lesiones

- óseas Líticas/ Trombopenia/ Alteraciones de las inmunoglobulinas. ISBN 978-84-7101-821-2
- Coordinator-Author of the Hematology chapters of the book “Diagnóstico, Tratamiento médico. Green Book”. Editorial Marban Edición 2012. ISBN 978-84-7101-830-4.
 - Coordinator-Author of the Hematology chapters of the book Diagnóstico, Tratamiento médico. Alteraciones analíticas. Editorial Marban 2013.. ISBN 978-84-7101-851-9
 - Coordinator-Author of the Hematology chapters of the book Diagnóstico, Tratamiento médico. Radiología. Editorial Marban 2013. ISBN 978-84-7101-849-6
 - Coordinator-Author of the Hematology chapters of the book Diagnóstico, Tratamiento médico, **Green Book**”. Editorial Marban Edición 2015.. ISBN 978-84-7101-979-0.
 - Coordinator-Author of the Hematology chapters of the book Medicina Interna 2. Digestivo. Reumatología. Endocrinología. Urología. Ginecología. Hematología. Dermatología. Editorial Marban, 2015. ISBN 978-84-7101-988-2.
 - Coordinator-Author of the Hematology chapters of the book Medicina Interna 4. Antimicrobianos. Antibióticos. VIH. Infecciosas. Hemoterapia. Oncología. Geriátría. Psiquiatría. Farmacología y Fármacos. Editorial Marban, 2015. ISBN 978-84-7101-990-5.
 - Coauthor of “Manual práctico de Aféresis”, 2019; ISBN 978-84-9494-7-2
 - Coauthor of Spanish ITP guidelines, 2020. ; ISBN papel: 978-84-09-28044-5.

PRESENTATIONS

Numerous publications and research in the area of ITP and thrombotic microangiopathy.

More than 100 abstracts and lectures in hematological congress and courses: European Bone Marrow Transplantation, European Hematology Association, International

Society Thrombosis and Haemostasis, Spanish Hematology Association, Madrid
Hematology Association, American Society of Haematology, etc.

Madrid 3 de enero de 2022
Cristina Pascual Izquierdo